Signal
GSK expands FDA approval for RSV vaccine Arexvy to younger adults at risk
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-03-13 15:54 UTCUpdated 2026-03-13 16:27 UTC
rss
clinical_trialsfdaapprovalsdrug_development
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
GSK has achieved a significant regulatory advancement with the FDA's expanded approval of its RSV vaccine Arexvy for younger adults aged 18 to 49 at increased risk of RSV-related lower respiratory tract disease. This approval places GSK on equal footing with Pfizer and Moderna, who previously secured FDA endorsements for their RSV vaccines. The broader clearance comes at a time when Arexvy's sales growth has plateaued, offering potential to boost uptake in a competitive and difficult vaccine market.
Entities
GSKPfizerModernaArexvy
Score total
0.98
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Follows recent FDA approvals of RSV vaccines by Pfizer (2025) and Moderna (2024).
- Responds to a difficult regulatory environment for vaccine makers.
- Addresses a market need for broader RSV vaccination coverage in younger at-risk adults.
Why it matters
- Expands protection options for younger adults at risk of RSV-related respiratory disease.
- Positions GSK competitively alongside Pfizer and Moderna in the RSV vaccine market.
- May help reverse flattening sales trends for Arexvy amid a challenging vaccine regulatory landscape.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: medium
Recurring claims
- GSK's RSV vaccine Arexvy received FDA approval for use in adults aged 18 to 49 at increased risk of RSV-related lower respiratory tract disease.
- The FDA expansion puts GSK on par with Pfizer and Moderna, who obtained RSV vaccine approvals in 2025 and 2024 respectively.
How sources frame it
- BioPharma Dive: neutral
- Fierce Pharma: neutral
All evidence
All evidence
GSK has secured an FDA expansion for its respiratory syncytial virus vaccine, Arexvy, for adults ages 18 to 49 who are at increased risk of lower respiratory tract disease cause...
Fierce Pharma (All) · fiercepharma.com · 2026-03-13 16:27 UTC
GSK’s RSV vaccine wins broader FDA clearance
BioPharma Dive · biopharmadive.com · 2026-03-13 15:54 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Pharma (All) (1)
- BioPharma Dive (1)
Top origin domains (this list)
- fiercepharma.com (1)
- biopharmadive.com (1)